News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
301,113 Results
Type
Article (15001)
Company Profile (295)
Press Release (285817)
Section
Business (91316)
Career Advice (158)
Deals (16116)
Drug Delivery (32)
Drug Development (53488)
Employer Resources (31)
FDA (6801)
Job Trends (5519)
News (164658)
Policy (12295)
Tag
Academia (946)
Alliances (25873)
Alzheimer's disease (783)
Approvals (6782)
Artificial intelligence (65)
Bankruptcy (103)
Best Places to Work (4732)
Biotechnology (245)
Breast cancer (72)
Cancer (735)
Cardiovascular disease (63)
Career advice (139)
CAR-T (57)
Cell therapy (182)
Clinical research (42543)
Collaboration (252)
Compensation (101)
COVID-19 (1083)
C-suite (71)
Cystic fibrosis (66)
Data (831)
Diabetes (75)
Diagnostics (1638)
Earnings (33337)
Events (50695)
Executive appointments (200)
FDA (7127)
Funding (258)
Gene editing (55)
Gene therapy (151)
GLP-1 (320)
Government (1184)
Healthcare (7071)
Infectious disease (1120)
Inflammatory bowel disease (97)
IPO (8003)
Job creations (1037)
Job search strategy (134)
Layoffs (188)
Legal (2118)
Lung cancer (118)
Manufacturing (80)
Medical device (3472)
Medtech (3474)
Mergers & acquisitions (8229)
Metabolic disorders (232)
Neuroscience (997)
NextGen Class of 2024 (2118)
Non-profit (883)
Northern California (973)
Obesity (127)
Opinion (91)
Parkinson's disease (62)
Patents (54)
People (27514)
Phase I (14643)
Phase II (19601)
Phase III (12834)
Pipeline (342)
Postmarket research (985)
Preclinical (6157)
Radiopharmaceuticals (212)
Rare diseases (174)
Real estate (1860)
Regulatory (9677)
Research institute (973)
Southern California (881)
Startups (2169)
United States (7909)
Vaccines (169)
Weight loss (76)
Date
Today (82)
Last 7 days (466)
Last 30 days (2372)
Last 365 days (22052)
2024 (20239)
2023 (23965)
2022 (30247)
2021 (31138)
2020 (26589)
2019 (18343)
2018 (13442)
2017 (15635)
2016 (13739)
2015 (16811)
2014 (12452)
2013 (9312)
2012 (9526)
2011 (9706)
2010 (9313)
Location
Africa (193)
Arizona (50)
Asia (29557)
Australia (4279)
California (2200)
Canada (773)
China (190)
Colorado (82)
Connecticut (87)
Europe (43580)
Florida (236)
Georgia (63)
Illinois (132)
Indiana (54)
Japan (55)
Kansas (59)
Maryland (321)
Massachusetts (1782)
Minnesota (110)
New Jersey (585)
New York (631)
North Carolina (411)
Northern California (973)
Ohio (79)
Pennsylvania (438)
South America (272)
Southern California (881)
Texas (233)
Washington State (222)
301,113 Results for "chemomab therapeutics ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences - May 17, 2024
Chemomab Therapeutics Ltd. today announced upcoming scientific presentations at the Gordon Research Conference on Chemotactic Cytokines and at EASL 2024, the Annual Congress of the European Association for the Study of the Liver.
May 17, 2024
·
3 min read
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
Chemomab Therapeutics Ltd., a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the Aegis Virtual Conference on May 7, 2024 at 9:00 am ET. Dr. Mor’s presentation will be webcast live.
May 2, 2024
·
1 min read
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
Chemomab Therapeutics Ltd. today announced a new scientific publication that further confirms the important role of the soluble protein CCL24 in the pathologies underlying the rare fibrotic liver disease primary sclerosing cholangitis (PSC).
June 18, 2024
·
6 min read
Business
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, announced financial and operating results for the first quarter ended March 31, 2024, and provided a corporate update.
May 9, 2024
·
9 min read
Press Releases
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
November 15, 2024
·
13 min read
Business
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
Chemomab Therapeutics Ltd. announced the company will report its first quarter 2024 financial results and provide a business update on May 9, 2024, at 7:00 am Eastern Time.
April 24, 2024
·
1 min read
Press Releases
Chemomab Therapeutics to Present at October 2024 Investor Conferences
October 1, 2024
·
2 min read
Press Releases
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
October 30, 2024
·
1 min read
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
Chemomab Therapeutics Ltd. today reported that it presented two scientific posters supporting the clinical rationale for the company’s primary sclerosing cholangitis (PSC) program at EASL 2024, the Annual Congress of the European Association for the Study of the Liver, which is taking place June 5-8, 2024 in Milan, Italy.
June 6, 2024
·
7 min read
Policy
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Chemomab Therapeutics Ltd. announced that it received formal notification from the Listing Qualification Department of the Nasdaq Stock Market notifying the Company that it has been granted an additional 180-day compliance period, or until November 4, 2024, to regain compliance with Nasdaq’s minimum $1.00 bid price per share requirement.
May 8, 2024
·
4 min read
1 of 30,112
Next